Core Viewpoint - Weijie Chuangxin (688153.SH) announced the receipt of a government subsidy of 5 million yuan, which is expected to positively impact the company's operating performance for the fiscal year 2025 [1][5]. Financial Impact - The government subsidy accounts for approximately 21.07% of the net profit attributable to the parent company's shareholders for 2024 [5]. - For the first three quarters of 2025, Weijie Chuangxin reported revenue of 1.559 billion yuan and a net profit of 8.6 million yuan, indicating pressure on profitability amid increasing competition and costs [5]. Strategic Focus - The subsidy is intended to support the company's technological research and development as well as industrialization efforts, enhancing its innovation capabilities and market expansion [5]. - The company emphasizes its commitment to increasing R&D investment and advancing technology upgrades and product iterations to strengthen its competitive advantage in niche markets [5]. Future Outlook - Weijie Chuangxin plans to actively seek various compliant support resources in line with national and local industrial policies to promote collaborative development within the industry chain and enhance overall competitiveness and risk resilience [5].

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

格隆汇11月25日丨唯捷创芯(688153.SH)公布，公司2025年11月24日收到政府补助款项人民币500万元， 为与收益相关的政府补助，占公司2024年归母净利润绝对值的比例为21.07%。 ...

人民财讯11月25日电，唯捷创芯(688153)11月25日公告，公司11月24日收到政府补助款项500万元，为 与收益相关的政府补助，占公司2024年归母净利润绝对值的比例为21.07%。 ...

唯捷创芯（天津）电子技术股份有限公司（以下简称"公司"）2025 年 11 月 24 日收到政府补助款项人民币 500 万元，为与收益相关的政府补助，占公司 2024 年归母净利润绝对值的比例为 21.07%。 二、补助的类型及对上市公司的影响 唯捷创芯（天津）电子技术股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 证券代码：688153 证券简称：唯捷创芯 公告编号：2025-069 根据《企业会计准则第 16 号——政府补助》等有关规定，公司已确认上述 事项并划分补助类型，上述获得的政府补助预计将对公司利润产生一定影响。 上述政府补助数据未经审计，具体会计处理以及对公司损益的影响最终以审 计机构年度审计确认后的结果为准。敬请投资者注意投资风险。 特此公告。 唯捷创芯（天津）电子技术股份有限公司董事会 2025 年 11 月 26 日 1 ...

Core Points - Weijie Chuangxin (688153.SH) closed at 33.70 yuan, with a decline of 2.40%, currently in a broken state [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 12, 2022, with an initial public offering of 40.08 million shares at a price of 66.60 yuan per share [1] - The total amount raised from the IPO was 266,932.80 thousand yuan, with a net amount of 250,251.13 thousand yuan after deducting issuance costs [1] - The final net amount raised exceeded the original plan by 1,529.31 thousand yuan [1] - According to the prospectus disclosed on April 7, 2022, the funds were intended for integrated circuit production testing projects, R&D center construction projects, and to supplement working capital [1] Financial Details - The total issuance costs for the IPO amounted to 16,681.67 thousand yuan, with underwriting and sponsorship fees accounting for 14,731.30 thousand yuan [2]

Core Points - The Shanghai Composite Index is at 4008.92 points, above the annual line, with a change of 0.22% [1] - A total trading volume of A-shares reached 894.89 billion yuan today [1] - 39 A-shares have surpassed the annual line, with notable stocks including Hangxin Technology, Liwang Co., and Chuanfa Longmang, showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 4008.92 points, reflecting a 0.22% increase [1] - The total trading volume for A-shares today is 894.89 billion yuan [1] Stocks Surpassing Annual Line - 39 A-shares have crossed the annual line, with the highest deviation rates recorded for: - Hangxin Technology: 4.59% - Liwang Co.: 3.56% - Chuanfa Longmang: 3.27% [1] - Other stocks with smaller deviation rates include: - Jiuzhou Group - Dali Kaipu - Tiens Wind Power [1] Detailed Stock Data - Notable stocks and their performance: - Hangxin Technology: +4.52%, turnover rate 5.95%, latest price 17.34 yuan, deviation rate 4.59% [1] - Liwang Co.: +5.42%, turnover rate 5.46%, latest price 28.02 yuan, deviation rate 3.56% [1] - Chuanfa Longmang: +3.57%, turnover rate 3.12%, latest price 13.07 yuan, deviation rate 3.27% [1]

Core Viewpoint - The company, Vanchip, is holding a Q3 2025 earnings presentation to provide insights into its operational performance and financial status, allowing investors to engage and ask questions [3][4]. Group 1: Meeting Details - The earnings presentation is scheduled for November 17, 2025, from 15:30 to 16:30 [2][4]. - The event will take place online at the Shanghai Securities Journal and China Securities Network Roadshow Center [2][4]. - Investors can submit questions via email to the company's investor relations before the meeting [2][4]. Group 2: Participants - Key participants include the General Manager, Sun Yijun, the Financial Officer, Xin Jing, the Board Secretary, Zhao Yanping, and Independent Director, Yang Dan [4]. Group 3: Participation Method - Investors can log in to the online platform during the scheduled time to participate and ask questions [4][6]. - Questions can be sent via email to IR@vanchip.com by November 16, 2025, at 18:00 [4][6]. Group 4: Contact Information - The contact for inquiries is the Board Office, reachable at 010-84298116-3666 or via email at IR@vanchip.com [6]. Group 5: Additional Information - After the meeting, investors can access the presentation details and main content through the online platform [6].

唯捷创芯（天津）电子技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688153 证券简称：唯捷创芯 公告编号：2025-068 会议召开地点：上海证券报·中国证券网路演中心（https://roadshow.cnstock. com/） 1 会议召开方式：网络文字互动 重要内容提示： 会议召开时间：2025 年 11 月 17 日（星期一）15:30-16:30 会 议 召 开 地 点 ： 上 海 证 券 报 · 中 国 证 券 网 路 演 中 心 （https://roadshow.cnstock.com/） 会议召开方式：网络文字互动 投资者可于 2025 年 11 月 16 日（星期日）18:00 前，将需要了解的情况 和相关问题，通过电子邮件的形式发送至公司投资者关系邮箱 IR@vanchip.com。 公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 唯捷创芯（天津）电子技术股份有限公司（以下简称"公司"）已于 2025 ...

Core Insights - The company has achieved significant revenue in the Wi-Fi sector, particularly in mobile phones, routers, and AI edge applications, and holds a leading position in this field [2] - The company is currently tracking and gaining insights into cutting-edge technologies related to computing infrastructure and optical switching [2] - The company identifies power consumption and latency as the core bottlenecks in the future communication sector, aligning with its core advantages in radio frequency technology, which emphasizes high linearity, low power consumption, and low latency [2] - The core strategy of the company is to continue focusing on its radio frequency main business while actively exploring potential synergies between its core capabilities and future computing networks, with careful planning to follow once the technological evolution path is clear [2]